Changes in regulations are reducing costs, expediting approval, and increasing the market for biosimilars.
Kimberly Salgado
Advertisement
Kimberly Salgado is Head of Centre for Biosimilar Drug Development, ICON plc
Articles by Kimberly Salgado
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
5